Legal entity
regulation is the sole category represented across all 1 tracked stories. 340B Drug Pricing Program is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window.
Last mentioned: Aug 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. 340B Drug Pricing Program is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 2.3 for the same window. The 6 average consequence score is above the beat benchmark of 5.8 in the same window. We currently track 1 Legal story that mention April 2, 2026 Executive Order, all published on August 7, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 31 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering April 2, 2026 Executive Order. Shared-story counts are live from our verified record — not editorial picks.
The Trump administration’s generic drug tariff announcement raises critical legal questions. Without a Federal Register proclamation or annex of tariff lines, the impending 100% duty faces uncertainty under trade law. This analysis examines the Section 232 authority and the regulatory void affecting contracts and compliance.
Source: clinicalleader.com · pharmaceuticalonline.com
April 2, 2026 Executive Order is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
